Exciting advances in our knowledge of the epigenetics of multiple myeloma (MM) have recently been made. Speaking at the Myeloma 2017 meeting in Edinburgh, UK, Suzanne Lentzsch, MD, PhD from Columbia University, New York, NY, Brian Walker, PhD from the UAMS Myeloma Institute, Little Rock, AR and Wee Joo Chng, MB ChB, PhD, FRCP (UK), FRCPath (UK), FAMS from the National University Cancer Institute, Singapore, Singapore, discuss the highlights of the work that they presented in this area, developments in the field and identify key topics that are set to progress rapidly. Topics covered include panobinostat, a non-selective HDAC inhibitor, super-enhancers and targeting 1q24 gains. The panel also comment on the usefulness of WGS, RRBS and WES to improve our understanding of the epigenetics of MM.
Re-evaluating the role of epigenetics in multiple myeloma
